ModifiedUnitedHealthcarePolicy CS355NM.D

Surgery for the Prevention and Treatment of Lymphedema (New Mexico Only)

This policy governs the medical necessity and coverage stance for surgical procedures to prevent or treat lymphedema for UnitedHealthcare members in the state of New Mexico, covering techniques such as axillary reverse mapping, liposuction/lipectomy, microsurgical procedures (LVA, VLNT), and vascularized lymph node transfer.

Policy Summary

PayerUnitedHealthcare

PolicySurgery for the Prevention and Treatment of Lymphedema (New Mexico Only)

Policy CodePolicy CS355NM.D

Change TypeUpdated applicable CPT codes (added 1019T)

Effective DateFeb 1, 2026

Next Review Date

Key ActionFollow current coding and authorization procedures per plan; prior authorization likely required for complex lymphatic surgery and documentation of conservative therapy failure and specialist center experience may be requested.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable CPT codes to reflect annual edits and added 1019T.

SeveralEvidence syntheses cited

71 articlesStudies in review

69%ILR relative risk reduction

1%–46%Complication rate range

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Pooled lymphedema rate (ARM vs AD)

Coverage Criteria — Surgical Procedures for Lymphedema

inv-01: Not Medically Necessary Surgical Procedures

Covered stance when evaluated:

Not medically necessary: Surgical procedures for the prevention or treatment of lymphedema are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Procedures listed include but are not limited to Axillary Reverse Mapping (ARM), Liposuction/Lipectomy, Microsurgical treatment (including Lymphaticovenous Anastomosis/Lymphovenous bypass), and Vascularized Lymph Node Transfer.

inv-02: Liposuction / Lipectomy — candidate criteria

Liposuction/lipoaspiration (reductive procedures) — evidence-supported candidate profile

Liposuction candidate criteria: Adult patients with moderate-to-severe, chronic, nonpitting lymphedema (typically Stage II or Stage III) of the upper or lower extremity who have not responded adequately to conservative therapies (e.g., controlled compression therapy or complete decongestive therapy).Stage II or III; failure of conservative therapy

Evidence (systematic reviews and HTAs) suggests liposuction plus controlled compression therapy is associated with greater limb size reduction, fewer infections, and improved patient-reported outcomes versus compression alone, but the overall body of evidence is low quality and benefit is considered potential but unproven. Lifelong compression is typically required after reductive procedures.

inv-03: Microsurgical treatments — LVA and VLNT

Physiologic microsurgical procedures (LVA and VLNT) — evidence summary and candidate considerations

Microsurgical options: Lymphaticovenous anastomosis (LVA) or vascularized lymph node transfer (VLNT) may provide clinical improvement (circumference/volume reduction, fewer infections, improved quality of life) in selected patients with primary or secondary lymphedema refractory to conservative therapy.Varies by study (outcome measures and staging heterogeneous)

Pooled analyses report variable mean clinical improvement (examples: pooled mean ~36.5% overall; LVA ~29% for UEL and ~32% for LEL; VLNT ~42% for UEL and ~39.5% for LEL) with high heterogeneity. Evidence quality is limited and comparative effectiveness versus other treatments remains uncertain; larger prospective trials are needed.

inv-04: Preventive microsurgical procedures (ILR / LYMPHA)

Immediate lymphatic reconstruction (ILR/LYMPHA) — preventive use at time of oncologic lymph node dissection

ILR preventive effect: Immediate LVA/ILR (LYMPHA) performed at the time of oncologic lymph node dissection is associated in pooled analyses with reduced rates of subsequent secondary lymphedema (examples include a reported ~69% relative risk reduction in one meta-analysis and lower cumulative incidence in several RCTs and cohort studies).Study diagnostic definitions and follow-up vary; some trials used relative volume change (RCV) ≥ 10% for lymphedema diagnosis

Evidence is low-to-moderate quality with heterogeneity and limited long-term follow-up; some studies report mixed oncologic safety signals in specific settings (e.g., small retrospective groin LVA series). Further high-quality randomized trials and longer follow-up are needed.

inv-05: Covered with clinical criteria and specialist center considerations

Evidence-based stance and conditions where procedures may be considered:

Preventive microsurgical procedures (LYMPHA/ILR): Considered promising for reducing incidence of lymphedema after axillary or inguinal lymph node dissection in selected patients based on pooled analyses, but evidence quality is limited by heterogeneity, variable diagnostics, and short follow-up.

Meta-analyses report varying effect sizes (examples: pooled upper extremity incidence after ILR ~2.75% in some series; risk ratio ~0.22 and NNT=4 in another); randomized data are limited and further standardization and trials are needed.

Lymphaticovenous anastomosis and vascularized lymph node transfer for treatment: LVA and VLNT can reduce severity of established lymphedema in carefully selected patients, with better outcomes in earlier stages but are not curative.

Professional society guidance (AAPS, ISL) supports these procedures as adjuncts to conservative therapy when done by experienced teams; systematic reviews and Cochrane note low-to-very-low certainty and call for well-designed RCTs.

Liposuction / debulking procedures: Specialized lymphatic liposuction is effective to reduce nonpitting fibrofatty components of chronic lymphedema when conservative therapy has failed, but requires lifelong compression and specialist multidisciplinary care.

Surgical procedures to prevent or treat lymphedema are considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy. Procedures explicitly listed in the policy include Axillary Reverse Mapping (ARM), Liposuction/Lipectomy, microsurgical treatments (for example, lymphaticovenous anastomosis/lymphovenous bypass), and vascularized lymph node transfer.

A small retrospective series of groin lymphaticovenous anastomosis performed at the time of inguinal lymph node dissection reported numerically higher tumor recurrence in the group that underwent LVA versus controls and raised concern for possible cancer spread via lymphatic channels; the authors concluded the finding warrants caution and further long-term study given the small sample size and methodological limitations.

NICE recommends that lymphovenous anastomosis during axillary or inguinal node dissection for prevention of secondary lymphedema should be performed only with special arrangements for clinical governance, consent, and audit or research. The guidance indicates further research is needed on patient selection, longer-term outcomes, limb volume safety, and oncologic implications before routine adoption.

This Medical Policy is provided for informational purposes to assist interpretation of UnitedHealthcare standard benefit plans; it does not constitute medical advice. Coverage decisions must follow applicable federal, state, or contractual benefit plan requirements, which govern in the event of conflict, and providers should verify plan-specific authorization and coding procedures prior to submission.

The policy restates that surgical interventions for prevention or treatment of lymphedema are not medically necessary because the available literature is heterogeneous and of limited quality, leaving uncertainty about long-term safety and comparative effectiveness. While some systematic reviews and case series report clinical improvement with procedures such as lymphovenous bypass, the overall low evidence quality precludes a conclusion that these surgeries are established, effective treatments.

Health technology assessments and systematic reviews consistently identify important limitations in the evidence: studies are often small, nonrandomized or retrospective, subject to heterogeneity in patient selection, outcome definitions, and follow-up duration, and report variable effect sizes. Meta-analyses and reviews (including Cochrane and multiple specialty-led HTAs) note possible reductions in limb volume, infection rates, and symptom burden for some procedures, but emphasize the predominance of low- or very low-certainty evidence and the need for well-designed randomized trials with standardized outcome measures and longer-term follow-up.

A Cochrane review concluded that there is currently insufficient high-quality evidence to support widespread adoption of lymphaticovenular anastomosis or vascularized lymph node transfer for the prevention or treatment of lymphedema, and called for well-designed randomized controlled trials comparing surgical approaches to each other and to standard non-surgical care.

Coding — Procedure and CPT References

Applicable Procedure Codes (reference)CPT

1019T	Lymphovenous bypass, including robotic assistance, when performed, per extremity.
15830	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy.
15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh.
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg.
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip.
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock.
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm.
15837	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand.
15838	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad.
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area.

1–10 of 17

1/2

Applicable CPT Codes (updated)CPT

1019T

Added to applicable CPT codes (lymphovenous bypass, per extremity) as noted in policy revision history.

inv-15: Relative volume change (RCV) threshold for lymphedema diagnosis used in trial

RCV thresholdRelative volume change (RCV) ≥ 10% used to define lymphedema diagnosis in the referenced randomized trial (Coriddi et al., NCT04241341)

Measurement windowRCV assessed at 6 through 24 months post-operatively per trial protocol

Diagnostic contextRCV ≥10% used alongside subjective symptoms and objective measures (bioimpedance, ICG) to define lymphedema in the study

inv-16: follow-up duration example

Example follow-up duration4‑year follow-up reported for LYMPHA/ILR in Levy et al. (Plast Reconstr Surg. 2023)

Typical trial follow-up

Provider Actions — Authorization, Documentation, and Billing

Prior Authorization

Prior Authorization and Coding

Prior authorization may be required for surgical procedures related to lymphedema. Submit authorization requests with the applicable CPT/HCPCS codes listed in this policy and any plan-specific code lists or tools. Inclusion of a code here is for reference only and does not guarantee coverage — check member-specific benefit terms and contract language.

Refer to the Applicable Codes section for procedure codes (e.g., 1019T, 15830–15839, 15847, 15876–15879, 38999, 49906).
Prior authorization rules vary by contract — verify member benefit and authorization requirements before scheduling.
Use plan authorization portals and any third‑party tools (e.g., InterQual) as required by the contract.

Documentation Required

Evidence Limitations Influencing Authorization

Documentation should clearly justify medical necessity given current evidence limitations. The published literature shows low-to-moderate quality evidence and heterogeneous outcomes for lymphedema surgical procedures — this uncertainty may affect authorization.

Background

Lymphedema is a chronic, progressive disorder caused by impaired lymphatic drainage leading to fluid accumulation and expansion of fibroadipose tissues. It may be congenital (primary) or acquired (secondary) from trauma, infection, surgery, or radiation. First-line management is conservative therapy such as complete decongestive therapy (CDT) including compression, skin care, manual lymphatic drainage, and exercise; surgical approaches are considered only when conservative measures fail or are inadequate, and evidence for surgical benefit remains limited.

Definitions — Procedures and Terms

inv-35: Axillary Reverse Mapping

DefinitionAxillary Reverse Mapping (ARM): A technique that injects blue dye in the upper extremity to allow visualization and preservation of lymphatic channels and lymph nodes during axillary lymph node dissection.

PurposeAims to identify and preserve arm-draining lymphatics during ALND to reduce risk of breast cancer–related lymphedema

Source attributionDefined in policy referencing Jena et al. experience and systematic reviews

inv-36: Liposuction/Lipectomy (definition)

DefinitionLiposuction/Lipectomy: A procedure that uses vacuum suction to remove subcutaneous adipose tissue in certain anatomical areas.

Clinical use

Revision History

2026-02-01codes_updatedLatest

Updated list of applicable CPT codes to reflect annual edits and added CPT code 1019T; previous policy version CS355NM.C was archived.

Policy Summary

PayerUnitedHealthcare

PolicySurgery for the Prevention and Treatment of Lymphedema (New Mexico Only)

Policy CodePolicy CS355NM.D

Change TypeUpdated applicable CPT codes (added 1019T)

Effective DateFeb 1, 2026

Next Review Date

SourceLink

On This Page

Guidelines (AAPS, ISL, NICE) recommend use in specialist centers with multidisciplinary teams; evidence is low quality and benefit considered potential but unproven in some HTAs.

Most microsurgical studies report ≥12 months follow-up; ILR trials report serial visits at 6 weeks then every 6 months to 24 months

Reporting impactShorter follow-up in many studies limits assessment of long‑term durability; some single‑arm reports and RCTs have incomplete 24‑month data

Provide clinical history showing failure of conservative therapy and staging (e.g., ISL stage, Cheng grade, Campisi), prior treatments, and objective measures of limb volume or circumference.
Summarize supporting evidence for the proposed procedure and reference pertinent diagnostic testing (e.g., ICG lymphangiography, bioimpedance, near-infrared fluorescence imaging) when used to document candidacy.
Be aware that systematic reviews and HTAs describe potential but unproven benefit; authorization decisions will consider the limited and heterogeneous evidence base.

Documentation Required

Plan/Contract Conformity Required

Ensure proposed services conform to the member's plan, state and federal contract terms. When benefit language conflicts with this policy, the contract governs. Use the member-specific certificate or evidence of coverage to determine covered services and prior authorization pathways.

Verify federal, state or contractual requirements for coverage prior to rendering services.
If a service is excluded or limited by the member’s contract, do not assume coverage based on this policy alone.
When in doubt, obtain an authorization determination in writing before performing the procedure.

Documentation Required

Specialist Center and Team Documentation

For procedures that are considered complex (e.g., microsurgical LVA, VLNT, specialized lymphatic liposuction), documentation should demonstrate multidisciplinary evaluation and specialist expertise. Authorization is more likely to be supported when care is delivered at high‑volume centers with appropriate team composition.

Include documentation of multidisciplinary evaluation (lymphedema surgeon, certified lymphedema therapist, physiatrist/rehabilitation specialist, nursing/therapy support).
Provide evidence of surgeon and center experience (case volumes, microsurgery training, accreditation, or referral center designation).
Detail perioperative and long‑term care plan, including requirement for lifelong compression following liposuction when applicable.

Documentation Required

Conservative Therapy Prerequisite

Conservative therapy must be documented as attempted and inadequate before requesting authorization for reductive or microsurgical procedures for lymphedema.

Document completion and duration of complete decongestive therapy (CDT) components: manual lymphatic drainage, compression garments, limb care/skin hygiene, exercise, and any pneumatic compression used.
Specify duration and adherence to conservative measures and objective measures showing insufficient response (e.g., persistent nonpitting edema, measured volume/circumference unchanged).
For liposuction specifically, show prior controlled compression therapy (CCT/CDT) failure and stage of disease (typically Stage II–III) as described in the literature.

Used as reductive surgery for moderate-to-severe, nonpitting lymphedema (often Stage II–III) when conservative therapy has failed; typically followed by controlled compression therapy

Evidence noteHayes HTA reports potential but unproven benefit with low-quality evidence showing limb size reduction and fewer infections when combined with compression

inv-37: Lymphaticovenous Anastomosis (definition)

DefinitionLymphaticovenular/Lymphaticovenous Anastomosis (LVA): A surgical procedure that connects small lymphatic vessels to adjacent venules to shunt excess lymphatic fluid.

Clinical intentProvides a physiologic bypass to improve lymphatic drainage for secondary peripheral lymphedema; number of anastomoses reported varies (mean ~3–4 per LVA series)

Evidence noteSystematic reviews report clinical and durable edema relief but overall low quality evidence limits confidence in conclusions

inv-38: Lymphedema (definition)

DefinitionLymphedema: The build-up of fluid in soft body tissues when the lymph system is damaged or blocked.

EtiologyCan be primary (congenital) or secondary (e.g., trauma, infection, cancer surgery/radiation)

Clinical courseChronic, progressive condition that may include fluid accumulation and hypertrophic fat deposition

inv-39: Vascularized Lymph Node Transfer (definition)

DefinitionVascularized Lymph Node Transfer (VLNT): A surgical procedure that transfers skin, fat, and lymph nodes for lymphatic reconstruction.

Clinical outcomesStudies report variable circumference/volume reduction and fewer cellulitis episodes; pooled reductions and complication rates vary across series

Evidence noteHayes and meta-analyses describe low-quality evidence suggesting benefit in selected patients refractory to conservative therapy

inv-40: Liposuction/Lipectomy (alternate chunk)

Alternate definitionLiposuction/Lipectomy (alternate): Reductive surgical removal of excess adipose/fibroadipose tissue often followed by controlled compression therapy for chronic nonpitting lymphedema unresponsive to conservative measures.

Patient selectionUsed for adults with moderate-to-severe nonpitting lymphedema of upper or lower extremities; evidence primarily low quality HTA findings

Outcome measuresStudies reported limb size/volume reduction, infection rate changes, ROM, and patient‑reported outcomes

inv-41: Lymphaticovenous Anastomosis (LVA) — alternate chunks

Alternate definitionLymphaticovenous Anastomosis (LVA) — alternate: Microsurgical anastomosis between lymphatic collectors and venules to provide lymphatic drainage; reported mean number of anastomoses ~3.39 (UEL) to 4.50 (LEL) in pooled series.

Post-op careMost studies report postoperative compression therapy and manual drainage; follow-up typically ≥12 months

Evidence qualityECRI and systematic reviews note LVA appears safe with durable edema relief but overall evidence quality is low

inv-42: Vascularized Lymph Node Transfer (VLNT) — alternate chunks

Alternate definitionVascularized Lymph Node Transfer (VLNT) — alternate: Transfer of vascularized lymph node–containing tissue from donor sites (e.g., groin, gastroepiploic, submental, jejunal) to the affected region to restore lymphatic function.

Reported outcomesCircumferential/volume reduction rates vary widely (e.g., CRRs 34–43% upper extremity; up to 54.6% below knee in some series) and cellulitis episodes reduced in many reports

ComplicationsPooled donor-site complication rates low (~1.4%) and recipient-site complications ~3.2% in some meta-analyses; overall heterogeneity and low study quality noted

inv-43: Immediate Lymphatic Reconstruction (ILR) / LYMPHA

DefinitionImmediate Lymphatic Reconstruction (ILR)/LYMPHA: Preventive microsurgical lymphatic reconstruction (e.g., lymphaticovenous anastomosis or bypass) performed at time of oncologic lymph node dissection to reduce subsequent risk of secondary lymphedema.

Evidence summarySystematic reviews and meta-analyses report reduced rates of secondary lymphedema with ILR (e.g., pooled RR reductions and single-cohort pooled cumulative rates ~5% in some analyses), but evidence quality is low and heterogeneity exists

Trial exampleCoriddi randomized trial used ILR when technically feasible with at least one bypass; follow-up included serial assessments and RCV definitions (RCV ≥10%)

inv-44: LYMPHA / Immediate Lymphatic Reconstruction (definition duplicate)

Duplicate definitionLYMPHA / Immediate Lymphatic Reconstruction (ILR): Preventive microsurgical lymphatic reconstruction at time of lymph node dissection intended to reduce incidence of cancer-related lymphedema.

Reported incidenceStudies report ILR-associated BCRL rates ranging from ~2–16% with control rates higher; meta-analyses report risk ratio ~0.22 and NNT=4 in some pooled analyses

LimitationsLack of long-term randomized data, variable diagnostic criteria, and heterogenous techniques limit definitive conclusions

inv-45: Lymphaticovenous anastomosis (LVA) — definition duplicate

Duplicate definitionLymphaticovenous anastomosis (LVA): A supermicrosurgical procedure connecting lymphatic channels to venules to reduce lymphatic congestion and severity of lymphedema.

Clinical contextUsed for secondary peripheral lymphedema; pooled mean clinical improvement reported (~36.5% in Hahn 2025) with high heterogeneity

Evidence cautionECRI concluded benefits likely but evidence quality limits confidence; larger prospective studies required

inv-46: Vascularized lymph node transfer (VLNT) — definition duplicate

Duplicate definitionVascularized lymph node transfer (VLNT): Transfer of vascularized lymph nodes to an affected area to restore lymphatic function and reduce lymphedema severity.

Guideline gradingAAPS guideline: VLNT has evidence supporting effectiveness (GRADE 1B); surgery should be performed at experienced centers

OutcomesMeta-analyses report substantial circumferential/volume reductions and decreased cellulitis but overall low quality evidence and high heterogeneity

inv-47: Liposuction (lymphatic liposuction, debulking) — definition alt

Alternate liposuction termLiposuction (lymphatic liposuction, debulking): Surgical removal of excess adipose/fibroadipose tissue for nonpitting, fibrotic lymphedema, usually combined with lifelong compression therapy.

ScopeApplied to severe fibrosclerotic lymphedema (including elephantiasis) and head/neck treatment-related lymphedema in select reports

Multidisciplinary careISL and other guidance recommend specialized teams (surgeons, therapists) for lymphatic liposuction procedures

inv-48: LYMPHA / immediate lymphatic reconstruction — referenced in reviews

Referenced in reviewsLYMPHA / immediate lymphatic reconstruction is cited across systematic reviews and HTAs as a promising preventive approach for BCRL with multiple ongoing RCTs, but evidence is low-quality overall.

Guidance contextECRI and Hayes assessments summarize consistent but low-quality evidence; randomized trials (e.g., Coriddi) provide preliminary RCT data

Research recommendationAuthors and HTAs call for standardized techniques, diagnostic criteria, and longer follow-up in future trials

inv-49: lymphovenous anastomosis (LVA) — references and guidance

References and guidanceLymphovenous anastomosis (LVA) is discussed in ECRI and Hayes assessments and NICE IPG785; reviews note apparent safety and clinical benefit but emphasize low-quality evidence and need for further research.

Clinical applicationNICE recommends LVA during axillary or inguinal node dissection only with special arrangements for governance, consent, audit or research

Evidence gapsHeterogeneity in patient selection, technique, and outcome measurement limits generalizability

inv-50: vascularized lymph node transfer (VLNT) — references and guidance

References and guidanceVascularized lymph node transfer (VLNT) is supported by AAPS and ISL guidance as effective in selected patients; multiple systematic reviews and meta-analyses report volume reduction and fewer infections but note low-quality evidence.

Complication ratesMeta-analyses report low pooled donor- and recipient-site complication rates but overall complication rates across procedures vary widely

Practice implicationVLNT should be performed at experienced centers with multidisciplinary teams and patient selection based on failure of conservative therapy